• Je něco špatně v tomto záznamu ?

Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats

Š. Jíchová, Š. Doleželová, L. Kopkan, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,

. 2016 ; 352 (6) : 618-630. [pub] 20160927

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023455

BACKGROUND: Malignant hypertension is a life-threatening condition, and its pathophysiology is still poorly understood. The present study was designed to evaluate the role of interaction of the renin-angiotensin system with 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway, in the pathophysiology of angiotensin II (ANG II)-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. METHODS: Malignant hypertension was induced by 12 days׳ dietary administration of 0.3 % indole-3-carbinol (I3C), a natural xenobiotic that activates a mouse renin gene. We hypothesized that chronic administration of fenofibrate, 190mg/kg body weight, a lipid-lowering drug, should increase renal production of 20-HETE, a tubular transport inhibitor; an expected increase in sodium excretion would oppose the development of ANG II-dependent malignant hypertension. Blood pressure was monitored by radiotelemetry, and at the end of the experiment rats were prepared for renal functional studies to evaluate in vivo the pressure-natriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP). RESULTS: In I3C-induced rats, the treatment with fenofibrate significantly attenuated hypertension and improved the slope of the pressure-natriuresis relationship. Although fenofibrate treatment increased kidney gene and protein expression of CYP4A1, a major isoform responsible for 20-HETE formation, it did not increase renal 20-HETE concentration. On the contrary, fenofibrate treatment significantly suppressed renin gene expression, plasma renin activity and plasma and kidney ANG II levels. CONCLUSIONS: Fenofibrate treatment significantly attenuated the course of malignant hypertension in I3C-induced CYP1a1-Ren-2 transgenic rats, and the mechanism responsible for antihypertensive action was fenofibrate-induced suppression of renin-angiotensin system activity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023455
003      
CZ-PrNML
005      
20180930132909.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.amjms.2016.09.008 $2 doi
035    __
$a (PubMed)27916218
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats / $c Š. Jíchová, Š. Doleželová, L. Kopkan, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,
520    9_
$a BACKGROUND: Malignant hypertension is a life-threatening condition, and its pathophysiology is still poorly understood. The present study was designed to evaluate the role of interaction of the renin-angiotensin system with 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway, in the pathophysiology of angiotensin II (ANG II)-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. METHODS: Malignant hypertension was induced by 12 days׳ dietary administration of 0.3 % indole-3-carbinol (I3C), a natural xenobiotic that activates a mouse renin gene. We hypothesized that chronic administration of fenofibrate, 190mg/kg body weight, a lipid-lowering drug, should increase renal production of 20-HETE, a tubular transport inhibitor; an expected increase in sodium excretion would oppose the development of ANG II-dependent malignant hypertension. Blood pressure was monitored by radiotelemetry, and at the end of the experiment rats were prepared for renal functional studies to evaluate in vivo the pressure-natriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP). RESULTS: In I3C-induced rats, the treatment with fenofibrate significantly attenuated hypertension and improved the slope of the pressure-natriuresis relationship. Although fenofibrate treatment increased kidney gene and protein expression of CYP4A1, a major isoform responsible for 20-HETE formation, it did not increase renal 20-HETE concentration. On the contrary, fenofibrate treatment significantly suppressed renin gene expression, plasma renin activity and plasma and kidney ANG II levels. CONCLUSIONS: Fenofibrate treatment significantly attenuated the course of malignant hypertension in I3C-induced CYP1a1-Ren-2 transgenic rats, and the mechanism responsible for antihypertensive action was fenofibrate-induced suppression of renin-angiotensin system activity.
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $7 D001794
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $7 D019363
650    _2
$a cytochrom P450 CYP4A $x metabolismus $7 D042926
650    _2
$a fenofibrát $x farmakologie $x terapeutické užití $7 D011345
650    _2
$a hodnoty glomerulární filtrace $x účinky léků $7 D005919
650    _2
$a homeostáza $x účinky léků $7 D006706
650    _2
$a kyseliny hydroxyeikosatetraenové $x metabolismus $7 D006893
650    _2
$a hypertenze maligní $x chemicky indukované $x farmakoterapie $7 D006974
650    _2
$a indoly $7 D007211
650    _2
$a ledviny $x metabolismus $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a natriuréza $x účinky léků $7 D009318
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renální oběh $x účinky léků $7 D012079
650    _2
$a renin $x genetika $7 D012083
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
650    _2
$a aktivace transkripce $7 D015533
655    _2
$a časopisecké články $7 D016428
700    1_
$a Doleželová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0227631
700    1_
$a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: luce@medicon.cz.
773    0_
$w MED00000305 $t The American journal of the medical sciences $x 1538-2990 $g Roč. 352, č. 6 (2016), s. 618-630
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27916218 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20180930133353 $b ABA008
999    __
$a ok $b bmc $g 1239136 $s 984368
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 352 $c 6 $d 618-630 $e 20160927 $i 1538-2990 $m The American journal of the medical sciences $n Am J Med Sci $x MED00000305
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...